Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair.
Neuraptive is preparing to launch a Phase 3 pivotal program for NTX-001 in early 2025. The program will consist of a single randomized, double-blind, placebo-controlled study assessing the efficacy and safety of NTX-001 in patients with peripheral nerve injury requiring repair. The final protocol for this single Phase 3 study is currently being discussed with the FDA. This follows the promising results from the Phase 2 NEUROFUSE study after 24 weeks. Neuraptive anticipates the full results, including all 48 weeks of data, to be available in the coming weeks and will look to share the results at an upcoming scientific conference.
“The FDA’s Breakthrough Therapy designation for NTX-001 is a major step forward in our mission to provide an innovative treatment for patients suffering from peripheral nerve injuries requiring repair,” said Evan L. Tzanis, COO and EVP of R&D at Neuraptive Therapeutics. “We are eager to continue working closely with the FDA to ensure NTX-001 reaches patients as quickly as possible and to deliver a transformative therapy in the field of nerve repair. We are grateful to the patients, investigators, and our partners who have remained committed to advancing NTX-001.”
With the continued advancement of NTX-001, Neuraptive Therapeutics, Inc., remains at the forefront of developing novel solutions for a significant number of patients affected by peripheral nerve injuries globally.
